Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Type of study
Language
Publication year range
1.
Cell Chem Biol ; 30(9): 1115-1134.e10, 2023 09 21.
Article in English | MEDLINE | ID: mdl-37467751

ABSTRACT

The immune checkpoint protein PD-L1 plays critical roles in both immune system homeostasis and tumor progression. Impaired PD-1/PD-L1 function promotes autoimmunity and PD-L1 expression within tumors promotes immune evasion. If and how changes in metabolism or defined metabolites regulate PD-L1 expression is not fully understood. Here, using a metabolomics activity screening-based approach, we have determined that hydroxyproline (Hyp) significantly and directly enhances adaptive (i.e., IFN-γ-induced) PD-L1 expression in multiple relevant myeloid and cancer cell types. Mechanistic studies reveal that Hyp acts as an inhibitor of autophagic flux, which allows it to regulate this negative feedback mechanism, thereby contributing to its overall effect on PD-L1 expression. Due to its prevalence in fibrotic tumors, these findings suggest that hydroxyproline could contribute to the establishment of an immunosuppressive tumor microenvironment and that Hyp metabolism could be targeted to pharmacologically control PD-L1 expression for the treatment of cancer or autoimmune diseases.


Subject(s)
B7-H1 Antigen , Interferon-gamma , Autophagy , B7-H1 Antigen/genetics , B7-H1 Antigen/metabolism , Cell Line, Tumor , Hydroxyproline , Interferon-gamma/pharmacology , Interferon-gamma/metabolism , Humans
2.
Science ; 369(6506): 993-999, 2020 Aug 21.
Article in English | MEDLINE | ID: mdl-32820126

ABSTRACT

Stimulator of interferon genes (STING) links innate immunity to biological processes ranging from antitumor immunity to microbiome homeostasis. Mechanistic understanding of the anticancer potential for STING receptor activation is currently limited by metabolic instability of the natural cyclic dinucleotide (CDN) ligands. From a pathway-targeted cell-based screen, we identified a non-nucleotide, small-molecule STING agonist, termed SR-717, that demonstrates broad interspecies and interallelic specificity. A 1.8-angstrom cocrystal structure revealed that SR-717 functions as a direct cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) mimetic that induces the same "closed" conformation of STING. SR-717 displayed antitumor activity; promoted the activation of CD8+ T, natural killer, and dendritic cells in relevant tissues; and facilitated antigen cross-priming. SR-717 also induced the expression of clinically relevant targets, including programmed cell death 1 ligand 1 (PD-L1), in a STING-dependent manner.


Subject(s)
Antineoplastic Agents/pharmacology , Biomimetic Materials/pharmacology , Membrane Proteins/metabolism , Nucleotides, Cyclic/pharmacology , Animals , B7-H1 Antigen/metabolism , Biomimetic Materials/chemistry , CD8-Positive T-Lymphocytes/drug effects , CD8-Positive T-Lymphocytes/immunology , Crystallography, X-Ray , Dendritic Cells/drug effects , Dendritic Cells/immunology , Humans , Killer Cells, Natural/drug effects , Killer Cells, Natural/immunology , Mice , Nucleotides, Cyclic/chemistry , Protein Conformation/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL